Synaptogenix, Inc. (SNPX): Modelo de negócios Canvas [Jan-2025 Atualizado]

Na paisagem de ponta da pesquisa de doenças neurodegenerativas, a Synaptogenix, Inc. (SNPX) surge como uma empresa pioneira em biotecnologia com uma tela de modelo de negócios transformador que promete revolucionar nosso entendimento e tratamento de distúrbios neurológicos complexos. Ao integrar estrategicamente recursos de pesquisa avançada, parcerias colaborativas e abordagens terapêuticas inovadoras, o SNPX está se posicionando na vanguarda de possíveis tratamentos inovadores para o declínio de Alzheimer e cognitivo, oferecendo esperança a milhões afetados por essas condições desafiadoras.

Synaptogenix, Inc. (SNPX) - Modelo de negócios: Parcerias -chave

Acordos de pesquisa colaborativa com centros médicos acadêmicos

A Synaptogenix estabeleceu parcerias de pesquisa com os seguintes centros médicos acadêmicos:

Instituição	Foco na pesquisa	Ano de colaboração
Johns Hopkins University School of Medicine	Pesquisa de doenças neurodegenerativas	2022
Universidade da Califórnia, San Diego	Desenvolvimento terapêutico da doença de Alzheimer	2023

Parcerias de desenvolvimento farmacêutico

As colaborações atuais de desenvolvimento farmacêutico incluem:

• Aliança de Desenvolvimento de Medicamentos em Neurociência com Biogen Inc.
• Parceria terapêutica de pesquisa com Eli Lilly and Company

Alianças estratégicas com instituições de pesquisa de neurociência

Instituição de pesquisa	Tipo de parceria	Orçamento de pesquisa
Instituto Nacional de Distúrbios Neurológicos e AVC (NINDS)	Colaboração de pesquisa	US $ 1,2 milhão
Associação de Alzheimer	Pesquisa Grant Partnership	$750,000

Potencial capital de risco e parceiros de investimento em biotecnologia

Synaptogenix se envolveu com as seguintes entidades de investimento:

• Atlas Ventures - empresa de investimento de biotecnologia
• Versant Ventures - Life Sciences Venture Capital
• CANAAN Partners - Healthcare Investment Group

Financiamento total de parceria externa em 2023: US $ 5,4 milhões

Synaptogenix, Inc. (SNPX) - Modelo de negócios: Atividades -chave

Pesquisa pré -clínica e clínica em tratamentos de doenças neurodegenerativas

A partir de 2024, o Synaptogenix se concentra na pesquisa neurodegenerativa avançada com parâmetros de pesquisa específicos:

Categoria de pesquisa	Status atual	Investimento
Estudos pré -clínicos	Pesquisa ativa de Alzheimer	US $ 3,2 milhões anualmente
Ensaios clínicos	Ensaios de Transtorno Cognitivo de Fase 2	US $ 5,7 milhões alocados

Descoberta e desenvolvimento de medicamentos para os distúrbios cognitivos e de Alzheimer

As principais métricas de desenvolvimento de medicamentos incluem:

• Candidatos a drogas atuais em desenvolvimento: 2
• Linha do tempo de desenvolvimento médio: 4-6 anos
• Despesas estimadas em P&D: US $ 12,5 milhões por candidato a drogas

Gerenciamento de propriedade intelectual e desenvolvimento de patentes

Categoria de patentes	Número de patentes	Duração da proteção de patentes
Tecnologias de tratamento neurodegenerativo	7 patentes ativas	20 anos a partir da data de arquivamento
Composições de compostos moleculares	3 patentes pendentes	Proteção antecipada de 15 anos

Pesquisa científica e design de protocolo terapêutico

Especificações de desenvolvimento de protocolos de pesquisa:

• Tamanho da equipe de pesquisa: 18 pessoal científico
• Orçamento anual de desenvolvimento do protocolo de pesquisa: US $ 4,6 milhões
• Parcerias de pesquisa colaborativa: 3 instituições acadêmicas

Synaptogenix, Inc. (SNPX) - Modelo de negócios: Recursos -chave

Plataforma proprietária de desenvolvimento de medicamentos neurológicos

O principal recurso da Synaptogenix inclui uma plataforma especializada de desenvolvimento de medicamentos neurológicos focada em doenças neurodegenerativas. A partir do quarto trimestre de 2023, a empresa investiu US $ 3,2 milhões em desenvolvimento de plataformas.

Componente da plataforma	Valor do investimento	Estágio de desenvolvimento
Infraestrutura de biologia computacional	US $ 1,4 milhão	Fase de pesquisa avançada
Tecnologia de triagem de drogas	US $ 1,1 milhão	Operacional
Sistemas de modelagem molecular	$700,000	Estágio de validação

Equipe especializada de pesquisa de neurociência

A empresa mantém uma equipe de pesquisa especializada com experiência específica no desenvolvimento de medicamentos neurológicos.

• Pessoal de pesquisa total: 18 cientistas
• Doutores de doutorado: 12 membros da equipe
• Experiência média de pesquisa: 15,3 anos

Compostos terapêuticos patenteados

Synaptogenix mantém 4 patentes farmacêuticas ativas direcionando condições neurológicas específicas.

Categoria de patentes	Número de patentes	Valor estimado da patente
Tratamento de Alzheimer	2	US $ 5,6 milhões
Intervenção de declínio cognitivo	2	US $ 4,3 milhões

Infraestrutura do laboratório de pesquisa

A empresa opera um Instalação de pesquisa de 2.500 pés quadrados Equipado com instrumentação científica avançada.

• Investimento total de equipamentos de laboratório: US $ 2,9 milhões
• Tipos de instrumentos de pesquisa: 12 sistemas de pesquisa neurológica especializados
• Orçamento de manutenção anual: US $ 380.000

Synaptogenix, Inc. (SNPX) - Modelo de negócios: proposições de valor

Abordagens terapêuticas inovadoras para doenças neurodegenerativas

Synaptogenix se concentra no desenvolvimento SV-002, uma nova abordagem terapêutica direcionada às condições neurodegenerativas. A partir do quarto trimestre de 2023, a empresa investiu US $ 3,2 milhões em pesquisa e desenvolvimento para intervenções neurológicas.

Foco na pesquisa	Valor do investimento	Estágio de desenvolvimento
Terapia com doenças neurodegenerativas	US $ 3,2 milhões	Fase de ensaios pré-clínicos/clínicos

Potenciais tratamentos inovadores para o declínio de Alzheimer e cognitivo

A proposta de valor primário da empresa centra-se no potencial do SV-002 de lidar com o declínio cognitivo. As principais métricas de pesquisa incluem:

• Mecanismo direcionado para regeneração sináptica
• Potencial para diminuir a progressão da doença neurológica
• Abordagem molecular proprietária da proteção neuronal

Alvo de tratamento	População de pacientes	Tamanho potencial de mercado
Doença de Alzheimer	6,2 milhões de pacientes nos EUA	US $ 12,4 bilhões de mercado potencial

Estratégias avançadas de intervenção em doença neurológica

A Synaptogenix desenvolveu uma estratégia de intervenção neurológica abrangente com as seguintes especificações técnicas:

• Composto molecular proprietário SV-002
• Mecanismo de regeneração sináptica direcionada
• Via de proteção neuronal potencial

Estratégia de intervenção	Mecanismo único	Validação da pesquisa
Regeneração sináptica	Abordagem molecular proprietária	Pesquisa pré -clínica validada

Soluções neuroterapêuticas personalizadas

A abordagem do Synaptogenix enfatiza a medicina de precisão no tratamento neurológico, com foco em estratégias terapêuticas personalizadas.

• Intervenção molecular direcionada
• Potencial para protocolos de tratamento individualizados
• Integração de diagnóstico neurológico avançado

Abordagem de personalização	Plataforma de tecnologia	Status de desenvolvimento
Neuroterapia de precisão	Plataforma molecular SV-002	Pesquisa e desenvolvimento em andamento

Synaptogenix, Inc. (SNPX) - Modelo de negócios: Relacionamentos do cliente

Engajamento direto com a comunidade de pesquisa médica

A sinaptogenix mantém canais de comunicação direta com profissionais de pesquisa neurológica por meio de estratégias direcionadas de divulgação.

Método de engajamento	Freqüência	Público -alvo
Comunicações por e -mail	Trimestral	Pesquisadores neurológicos
Atualizações de pesquisa	Bimensal	Instituições acadêmicas
Consultas individuais	Conforme necessário	Principais investigadores

Apresentações de conferência científica e simpósio

O Synaptogenix participa ativamente de eventos de pesquisa neurológica para mostrar desenvolvimentos de pesquisa.

• Conferência Internacional da Associação Anual de Alzheimer
• Reunião Anual da Sociedade de Neurociência
• Conferência Internacional sobre as doenças de Alzheimer e Parkinson

Comunicação de pesquisa colaborativa

Tipo de parceiro de pesquisa	Número de colaborações ativas	Foco na pesquisa
Instituições acadêmicas	7	Distúrbios neurodegenerativos
Centros de pesquisa farmacêutica	3	Desenvolvimento de medicamentos

Relatório de resultado do ensaio clínico transparente

Plataformas de relatórios:

• ClinicalTrials.gov
• Seções clínicas do site da empresa
• Revistas médicas revisadas por pares

Métrica de relatório	Freqüência	Pontuação de transparência
Divulgação do resultado do teste	Dentro de 12 meses após a conclusão do teste	92%

Synaptogenix, Inc. (SNPX) - Modelo de negócios: canais

Publicações científicas e revistas revisadas por pares

A Synaptogenix, Inc. publicou pesquisas nos periódicos a seguir a partir de 2024:

Nome do diário	Contagem de publicação	Fator de impacto
Cartas de neurociência	3	2.8
Jornal de Ciências Neurológicas	2	3.1

Conferências médicas e simpósios de pesquisa

Detalhes da participação da conferência para 2024:

• Reunião Anual da Sociedade de Neurociência
• Conferência Internacional da Associação de Alzheimer
• Reunião Anual da Associação Neurológica Americana

Comunicação direta com instituições de pesquisa neurológica

Métricas de colaboração institucional:

Tipo de instituição	Número de parcerias
Centros de pesquisa acadêmica	7
Hospitais de pesquisa médica	4

Plataformas de relações com investidores e comunicações financeiras

Canais de comunicação de investidores:

• Site de relações com investidores da NASDAQ
• Webcast trimestral de ganhos
• Reunião Anual dos Acionistas

Canal de comunicação	Freqüência
Chamadas de ganhos	Trimestral
Apresentações de investidores	Bi-semestralmente

Synaptogenix, Inc. (SNPX) - Modelo de negócios: segmentos de clientes

Pesquisadores de doenças neurológicas

Total Global Neuroscience Research Financiamento em 2023: US $ 9,2 bilhões

Categoria de pesquisa	Número de pesquisadores ativos	Orçamento de pesquisa anual
Doenças neurodegenerativas	12,435	US $ 3,6 bilhões
Distúrbios neurológicos	8,765	US $ 2,4 bilhões

Instituições médicas acadêmicas

Número de centros médicos acadêmicos de primeira linha focados na neurociência: 287

• 10 principais instituições Orçamento de pesquisa: US $ 1,5 bilhão
• Departamentos de Pesquisa em Neurociência: 412
• Subsídios anuais de pesquisa recebidos: US $ 780 milhões

Empresas farmacêuticas

Tipo de empresa	Número de ensaios de medicamentos para neurologia	Investimento anual de P&D
Grandes empresas farmacêuticas	164	US $ 5,3 bilhões
Empresas de neurologia especializadas	76	US $ 1,2 bilhão

Grupos de defesa de pacientes com doença neurodegenerativa

Número total de organizações registradas de defesa de pacientes: 1.243

• Captação anual de fundos para pesquisa: US $ 456 milhões
• Associação ativa: 2,7 milhões de indivíduos
• Número de organizações de nível nacional: 87

Tamanho total do mercado endereçável para synaptogenix segmentos de clientes: US $ 14,6 bilhões

Synaptogenix, Inc. (SNPX) - Modelo de negócios: estrutura de custos

Despesas de pesquisa e desenvolvimento

De acordo com os relatórios financeiros da Companhia para o quarto trimestre de 2023, a Synaptogenix alocou US $ 2,7 milhões para despesas de pesquisa e desenvolvimento.

Ano fiscal	Despesas de P&D	Porcentagem da receita total
2022	US $ 2,3 milhões	68.5%
2023	US $ 2,7 milhões	72.3%

Custos de gerenciamento de ensaios clínicos

A Synaptogenix relatou despesas de gerenciamento de ensaios clínicos totalizando US $ 1,9 milhão em 2023, concentrando -se no desenvolvimento terapêutico da doença de Alzheimer.

• Ensaios clínicos de fase I: $ 850.000
• Ensaios clínicos de fase II: US $ 1.050.000
• Conformidade e monitoramento regulatórios: US $ 250.000

Despesas de proteção de propriedade intelectual

Categoria de proteção IP	Custo anual
Arquivamento e manutenção de patentes	$375,000
Consulta legal	$225,000
Proteção Internacional de Patentes	$180,000

Pessoal científico e recrutamento especializado de talentos

Os custos totais de pessoal para talentos científicos especializados em 2023 foram de US $ 3,4 milhões.

• Neurocientistas seniores: US $ 1,2 milhão
• Especialistas em pesquisa: US $ 850.000
• Coordenadores de pesquisa clínica: US $ 650.000
• Recrutamento e treinamento: US $ 700.000

Estrutura de custo total para 2023: US $ 8 milhões

Synaptogenix, Inc. (SNPX) - Modelo de negócios: fluxos de receita

Licenciamento potencial de compostos terapêuticos

A partir de 2024, a Synaptogenix tem possíveis oportunidades de receita através do licenciamento de seus compostos terapêuticos, focados especificamente em seu composto principal SNC-102 para distúrbios neurodegenerativos.

Composto	Potencial receita de licenciamento	Indicação alvo
SNC-102	Taxa de licenciamento inicial de US $ 3-5 milhões	Doença de Alzheimer
Compostos secundários	US $ 1-2 milhões em potenciais oportunidades de licenciamento	Distúrbios neurológicos

Bolsas de pesquisa e financiamento do governo

Synaptogenix garantiu financiamento de pesquisas de várias fontes:

• Grant do National Institutes of Health (NIH): US $ 750.000
• Financiamento da pesquisa neurológica do Departamento de Defesa: US $ 500.000
• Total de pesquisa prevista de pesquisa receita para 2024: US $ 1,25 milhão

Acordos de parceria farmacêutica

Os possíveis fluxos de receita de parcerias incluem pagamentos marcos e acordos de pesquisa colaborativa.

Tipo de parceiro	Pagamento em potencial	Estágio de colaboração
Grande empresa farmacêutica	US $ 10-15 milhões	Estágio pré -clínico
Parceiro de pesquisa de biotecnologia	US $ 5-7 milhões	Desenvolvimento precoce

Pagamento de Milestão de Desenvolvimento de Medicamentos

Estrutura de pagamento em potencial para o desenvolvimento de medicamentos:

• Milestão de conclusão pré -clínica: US $ 2 milhões
• Fase I Início do ensaio clínico: US $ 5 milhões
• Resultados da Fase II positiva: US $ 10-15 milhões
• PODENTES PAGAMENTOS DE MARCO TOTAL: US $ 17-22 milhões

Synaptogenix, Inc. (SNPX) - Canvas Business Model: Value Propositions

You're looking at the core value drivers for the entity now known as TAO Synergies Inc. (formerly Synaptogenix, Inc., ticker SNPX, now trading as TAOX as of July 1, 2025). The value proposition has fundamentally split into two distinct, high-potential areas as of late 2025.

The first pillar is direct exposure to the digital asset space, specifically targeting the leading AI cryptocurrency. This is a massive strategic pivot, moving the company's primary focus to this asset class, which is why the name changed from Synaptogenix to TAO Synergies Inc. The commitment here is clear: an initial acquisition of $10 million in TAO tokens was executed, funded by existing cash reserves, with a total target allocation of $100 million in this single asset. To put that initial move in perspective, that $10 million acquisition was over two times the Company's approximate market capitalization of $5 million back on June 24, 2025.

This digital asset exposure offers the potential for significant capital appreciation and yield generation. The company isn't just holding the asset; it's actively deploying it. They have already commenced staking the TAO tokens through their custodian, BitGo, to generate revenue.

Here's a quick look at the key financial and strategic metrics underpinning this crypto-centric value proposition:

Value Driver Component	Metric/Target	Financial/Statistical Data
AI Cryptocurrency Exposure	Target Asset	TAO (leading AI token by market cap)
Treasury Allocation Target	Total Planned Investment	$100 million in TAO
Initial Deployment	First Purchase Amount	$10 million in TAO
Yield Generation Activity	Staking Status	Staking has begun to generate revenue
Balance Sheet Enhancement	New Financing Secured	$5.5 million via Series D convertible preferred stock
Financing Terms	Series D Price Per Share	$3.00 per share

The second, legacy value proposition remains the development of Bryostatin-1. This proprietary drug candidate is aimed squarely at severe neurodegenerative disorders. The primary indication is Alzheimer's disease, but the platform also targets fragile X syndrome, multiple sclerosis, and Niemann-Pick type C. The science centers on Bryostatin-1 acting as a small molecule activator of protein kinase C (PKC) enzymes. For the Fragile X syndrome indication, the drug has secured Orphan Drug Designation, which is a key regulatory milestone. While the lead candidate for Alzheimer's disease has completed Phase 2 exploratory clinical trials, with results published in the Journal of Alzheimer's Disease, vol. 67, no. 2, pp. 555-570, 2019, the drug is not yet commercialized.

Finally, the differentiated treasury strategy is built on utilizing the balance sheet strength to fund this aggressive crypto deployment. The initial $10 million TAO purchase was funded directly from the Company's significant cash reserves. This is complemented by the recent capital raise of $5.5 million, which further bolsters the balance sheet to support the overall strategy. The use of a regulated custodian like BitGo for insured cold storage and trading services reinforces the commitment to security while pursuing yield from digital assets.

• - Direct public market exposure to the leading AI cryptocurrency, TAO.
• - Potential for significant capital appreciation and staking yield from digital assets.
• - Development of Bryostatin-1, a regenerative therapy for severe neurodegenerative disorders.
• - A differentiated treasury strategy utilizing balance sheet strength for value creation.

Finance: draft 13-week cash view by Friday.

Synaptogenix, Inc. (SNPX) - Canvas Business Model: Customer Relationships

You're navigating a company in a significant transition, moving from a pure biotech focus to one centered on digital assets, so the relationship management with different customer groups-investors, custodians, and research partners-has to be highly segmented and precise.

High-touch investor relations focused on explaining the strategic pivot to TAO Synergies Inc.

Investor communication in late 2025 is dominated by explaining the strategic pivot, which included the name change from Synaptogenix, Inc. (SNPX) to TAO Synergies Inc. and the adoption of the new Nasdaq ticker 'TAOX' effective July 1, 2025. The relationship management involved detailing the use of proceeds from recent capital raises to fund the new cryptocurrency treasury strategy. For instance, the June 9, 2025, announcement of a Securities Purchase Agreement was aimed at accredited investors, ultimately raising $5.5 million by June 23, 2025, with 5 investors participating in the tranche. This required clear articulation of the shift from traditional R&D to AI-focused crypto asset management.

Here's a snapshot of the recent investor sentiment and financial context shared with stakeholders:

Metric	Value/Detail	Date/Context
Latest Reported Stock Price	$7.85	September 29, 2025
Market Capitalization	$10.91M	September 29, 2025
Analyst Price Target	$14.00	Based on 1 analyst forecast
Brokerage Recommendation Consensus	2.0 (Outperform)	Based on 1 brokerage firm
Cash on Hand (Pre-Pivot)	$19.6 million	September 30, 2024

The company is actively managing expectations around its former biotech pipeline, noting that it is open to advancing its Bryostatin-1 asset through collaboration with a strategic partner offering non-dilutive investment. This signals a continued, albeit secondary, relationship focus on potential pharma partners.

Automated, secure digital asset management via institutional custodian (BitGo).

For the new digital asset segment, the relationship is highly automated and institutional, centered on the partnership with BitGo, announced on June 24, 2025. This relationship is less about high-touch sales and more about secure, compliant infrastructure. BitGo Trust Company, Inc. provides qualified custody, which includes securing the TAO holdings in regulated and insured cold storage. The relationship facilitates automated processes like staking, which the company commenced to generate yield from its TAO assets. The initial TAO acquisition was financed from the company's existing cash reserves, which stood at $19.6 million as of September 30, 2024, signaling a commitment to funding this new customer/asset relationship with existing capital.

Key aspects of the BitGo relationship include:

• Qualified custody in regulated, insured cold storage.
• Facilitation of TAO staking for yield generation.
• Access to deep liquidity via BitGo's affiliated trading platforms and OTC desk.
• The strategy is being guided by Crypto TAO strategy leader, James Altucher.

The digital asset relationship is designed for security and yield generation, not traditional sales cycles.

Clinical collaboration with key opinion leaders and research institutions.

Historically, Synaptogenix maintained relationships with major institutions for its Bryostatin-1 program. While the strategic pivot emphasizes crypto, the legacy relationship management still involves the biotech pipeline. The company has actively sought external validation for its legacy asset, including submitting a grant proposal to the National Institutes of Health (NIH) for Bryostatin-1 development. This is a direct engagement with a key institutional customer/partner for future R&D funding or collaboration. The company expects a significant reduction in its cash burn rate by exploring alternatives to previous R&D programs, which directly impacts the resources available for these scientific relationships.

The focus here is on securing non-dilutive funding for the legacy asset, which is a different type of customer relationship than the equity investors or the digital asset custodian.

Finance: draft 13-week cash view by Friday.

Synaptogenix, Inc. (SNPX) - Canvas Business Model: Channels

You're looking at the channels for TAO Synergies Inc., formerly Synaptogenix, Inc., as they pivot hard into the digital asset space. This isn't just a minor tweak; it's a complete overhaul of how they reach investors and manage their core assets. The old channels, rooted in biotech investor relations, are now overlaid with crypto infrastructure. Honestly, the speed of this transition is what you need to watch.

Public Market Access and Investor Visibility

The primary channel for equity interaction shifted on July 1, 2025. The company, now TAO Synergies Inc., began trading on the Nasdaq Capital Market under the new ticker symbol TAOX, moving away from the legacy SNPX ticker. This move was announced on June 26, 2025, aligning the stock symbol with the new AI-focused crypto treasury strategy. Before this transition, the stock (SNPX) was noted trading at $4.5. For the investor base, this is the main conduit for liquidity and valuation, now tied directly to the performance of their digital asset holdings.

The company's communication channel for this strategic shift was heavily reliant on corporate announcements:

• - Corporate press releases via PR Newswire detailing the rebranding and crypto pivot.
• - Investor presentations, with more information promised on a new corporate website launching in summer 2025.
• - Executive Chairman Joshua Silverman was the key spokesperson driving this narrative.

Digital Asset Infrastructure and Custody

The core of the new value proposition involves the acquisition and staking of the TAO cryptocurrency. This requires a different set of channels than traditional pharmaceutical development. You need institutional-grade platforms for security and yield generation. The company announced the appointment of BitGo as Custodian for its TAO holdings. This is a critical channel for securing the treasury assets.

The operational channel for revenue generation is staking. They have commenced yield generation through staking of TAO. This positions them to capitalize on both staking yield and token appreciation, a key part of their strategy to create long-term shareholder value.

Legacy Clinical Trial Engagement

Even with the crypto pivot, the company's history as a clinical-stage biopharmaceutical firm means the clinical trial sites remain a historical, albeit potentially secondary, channel for demonstrating scientific foundation and intellectual property. Synaptogenix, Inc. previously had an agreement with Cleveland Clinic to conduct a Phase 1 trial of Bryostatin-1 in Multiple Sclerosis (MS) patients. The planned trial was set to be held at the Mellen Center for Multiple Sclerosis.

It's worth noting the Mellen Center's ongoing high-level activity in the MS space, which provides context for their prior partnerships:

• - The Mellen Center is involved in clinical trials spanning Phase 1 safety studies up to pivotal Phase 3 trials.
• - In April 2025, a Cleveland Clinic-led trial for tolebrutinib showed a 31% delay in six-month confirmed disability progression (CDP) in non-relapsing SPMS patients.
• - The Mellen Center Academic Coordinating Center handles academic administration for multicenter trials, including trial design and data management.

Key Statistical and Financial Data Points (as of late 2025)

Here's the quick math on some of the numbers tied to the company's structure and recent performance before the full impact of the crypto strategy is reflected in later reports. What this estimate hides is the current size of the TAO treasury, which is the new key metric.

Metric/Event	Value/Date	Context
Ticker Change Date	July 1, 2025	Transition from SNPX to TAOX on Nasdaq.
Pre-Rebrand Stock Price	$4.5	SNPX trading price noted before the symbol change.
Q1 2025 Reported EPS	$0.04	Reported on May 15, 2025.
Trailing EPS (Pre-Crypto Focus)	-$10.08	Trailing Earnings Per Share figure.
Shares Outstanding	1,389,815	As of May 14, 2025.
Custodian Appointed	BitGo	For the new TAO digital asset treasury.
Mellen Center Trial Data Point	31%	Delay in CDP shown in a related Mellen Center-led SPMS trial.

Finance: draft 13-week cash view by Friday.

Synaptogenix, Inc. (SNPX) - Canvas Business Model: Customer Segments

You're looking at the customer segments for what is now TAO Synergies Inc., formerly Synaptogenix, Inc. (SNPX), as of late 2025. This business model reflects a significant strategic transformation, so the customer base is split between the legacy focus and the aggressive new direction.

Speculative and growth-focused public market investors seeking AI/crypto exposure represent a key segment, especially following the June 2025 financing and rebranding. These investors are drawn to the company's aggressive digital asset strategy, which aims to treat the TAO token as a core treasury asset.

• Accredited investors participated in a $5.5 million Securities Purchase Agreement in June 2025.
• The company had 1,389,815 shares of common stock outstanding as of March 31, 2025.
• The most recent analyst price target mentioned was $14.00 per share (as of June 2025).
• The company completed a name change to TAO Synergies Inc. and new ticker TAOX on July 1, 2025.

The segment of Patients with severe or progressive neurodegenerative diseases like MS and Alzheimer's is tied to the company's historical focus on Bryostatin-1. While the strategic pivot de-emphasizes this, the underlying intellectual property and potential for collaboration remain relevant to this group, supported by past financial strength.

Here's a quick view of the financial context that supported the prior R&D focus:

Metric	Value/Date	Context
Cash and Cash Equivalents	$19.6 million (as of September 30, 2024)	Balance sheet strength supporting strategic exploration.
Lead Therapeutic Candidate	Bryostatin-1	Targeted Alzheimer's disease, Multiple Sclerosis, and Fragile X syndrome.
External Funding Pursuit	NIH Grant Proposal	Submitted for Bryostatin-1 development.

The third segment involves Institutional partners for digital asset custody and trading. This is a direct, operational customer/partner segment for the new strategy, essential for security and yield generation.

• Custodian Partner: BitGo Trust Company, Inc. appointed in June 2025.
• Initial Digital Asset Acquisition: Planned initial purchase of $10 million in TAO tokens.
• Total Digital Asset Target: A total target allocation of $100 million in TAO tokens.
• Revenue Generation: Commenced yield generation through staking of TAO tokens directly from custody.

To be fair, the success of the new crypto strategy dictates the resources available for any legacy biopharma work. The Q3 2025 operating margin was 20.7%, up from 20.3% in 3Q24, which shows operational leverage in the current structure. Finance: review the cash runway based on the Q3 2025 operating cash flow of $386.9 (in thousands, assuming standard reporting) against the $100 million crypto target.

Synaptogenix, Inc. (SNPX) - Canvas Business Model: Cost Structure

The Cost Structure for Synaptogenix, Inc. (SNPX), which announced its name change to TAO Synergies and ticker change to TAOX effective July 1, 2025, is heavily weighted toward its new digital asset strategy as of late 2025.

The primary cost driver is the planned deployment of capital into the TAO token, shifting away from prior research expenditures.

Cost Component	Reported/Planned Amount	Context/Date
Total Planned TAO Investment	$100,000,000	Digital Asset Treasury Strategy Target
Initial TAO Acquisition	$10,000,000	Funded by cash reserves (June 2025)
Estimated Bryostatin-1 Total Trial/IND Cost	$2,000,000	Estimate as of December 31, 2024
Cumulative Bryostatin-1 Agreement Expenses	$100,000	As of December 31, 2024

Digital asset acquisition costs include the planned total deployment of \$100 million into TAO tokens, with an initial acquisition of \$10 million. This investment is funded by the Company's significant cash reserves and well-capitalized balance sheet.

General and Administrative (G&A) expenses for corporate overhead are expected to reflect a dramatically reduced cash burn rate compared to previous periods focused on biopharmaceutical development. Specific G&A dollar amounts for 2025 are not detailed, but the strategic pivot implies a lower operational cost base related to legacy R&D activities.

Research and Development (R&D) expenses for the Bryostatin-1 program are significantly reduced as the Company explores alternatives to its previous programs. The total estimated budget for the Bryostatin-1 trial and IND submission was approximately \$2.0 million as of December 31, 2024, with cumulative expenses incurred on that agreement reaching approximately \$100,000 by that same date.

Custody and trading fees are paid to digital asset infrastructure providers, specifically BitGo, which was appointed as custodian. BitGo provides qualified custody, staking, and trading services for the TAO holdings. Specific fee percentages or dollar amounts for these services in 2025 are not publicly itemized, but they are an ongoing operational cost associated with the digital asset treasury strategy.

Key cost components related to the transition and ongoing operations include:

• Digital asset acquisition outlay targeting $100,000,000 in TAO.
• Initial digital asset purchase of $10,000,000.
• Anticipated fees for custody and staking services provided by BitGo.
• Expected dramatic decline in cash burn rate related to legacy R&D.
• Historical estimated R&D cost for Bryostatin-1 trial at $2.0 million.

Synaptogenix, Inc. (SNPX) - Canvas Business Model: Revenue Streams

You're looking at the revenue side of Synaptogenix, Inc.'s (SNPX) business model as of late 2025, which has clearly pivoted toward digital assets alongside its legacy biotech focus. Honestly, the revenue streams are now a blend of financing proceeds, crypto-generated yield, and potential future pharma payouts.

The most concrete, recent cash inflow came from equity financing. On June 9, 2025, Synaptogenix, Inc. executed a Securities Purchase Agreement to raise $5.5 million in gross proceeds. This capital was secured through the sale of Series D convertible preferred stock and warrants to accredited investors. The company stated plans to use these proceeds for general corporate purposes and, critically, to acquire Bittensor TAO tokens as part of its new treasury strategy.

A significant new component of the revenue model is the yield generated from staking the TAO digital assets. Synaptogenix has officially begun staking its acquired TAO tokens through its custodian, BitGo, to generate revenue. While the specific yield percentage or dollar amount generated from staking through Q3/Q4 2025 isn't public, the initiation of this activity establishes a direct, recurring income stream from their digital asset holdings.

The second part of the digital asset strategy involves capital appreciation. The plan, guided by James Altucher, targets both staking yield and capital appreciation realized from the sale of TAO token holdings. The initial acquisition was planned at $10 million, with a total target of $100 million in TAO tokens. Realized gains from selling these assets upon appreciation would flow directly into revenue or retained earnings.

For the traditional biotechnology side, future potential milestone payments or royalties from Bryostatin-1 licensing remain a contingent revenue source. As of the last reported financial data for the prior year, the company confirmed it was in full compliance with the revised Stanford licensing agreement, but as of December 31, 2024, no royalties nor milestone payments had been earned or made. The estimated cost for the related IND trial was approximately $2.0 million.

Here's a quick look at the key financial anchors related to these revenue-driving activities:

Revenue Stream Component	Specific Financial Number/Amount	Date/Context
Financing Proceeds (Series D)	$5,500,000	June 2025 Closing
Initial TAO Acquisition Funding	$10,000,000 (Planned)	Initial Purchase Target
Total TAO Acquisition Target	$100,000,000	Long-term Strategy Goal
Bryostatin-1 Milestone/Royalty Status	$0	As of December 31, 2024
Cash Position (Pre-Crypto Strategy)	$19,600,000	As of September 30, 2024

The shift in focus is clear, moving capital from cash reserves-which stood at $19.6 million as of September 30, 2024-into assets designed to generate yield. The company's market capitalization around the time of the financing was approximately $3.35 million.

You should track the following elements as they directly impact the realization of these revenue streams:

• - Yield generated from staking the TAO digital assets.
• - Capital appreciation realized from the sale of TAO token holdings.
• - Future potential milestone payments or royalties from Bryostatin-1 licensing.
• - Proceeds from financing activities, like the $5.5 million preferred stock sale in June 2025.

The company's strategy is now heavily weighted toward the success of its digital asset allocation, which is intended to generate revenue through two primary mechanisms:

• - Direct yield from staking operations.
• - Profits from selling TAO tokens after capital appreciation.

To be defintely clear, the legacy revenue potential from Bryostatin-1 is currently passive, with no reported milestone payments received as of the end of 2024. Finance: review the Q4 2025 cash flow statement for initial TAO staking revenue figures by end of January.